C
CELLDEX THERAPEUTICS INC
NASDAQ: CLDX (Celldex Therapeutics, Inc.)
Last update: 12 hours ago39.18
2.28 (6.18%)
| Previous Close | 36.90 |
| Volume | 1,000,166 |
| Price / Sales | 16.20 |
| Price / Book | 4.06 |
| 52 Weeks Range |
| Operating Margin (TTM) | -9,027.19% |
| Diluted EPS (TTM) | -2.70 |
| Quarterly Revenue Growth (YOY) | 345.50% |
| Total Debt/Equity (MRQ) | 0.49% |
| Current Ratio (MRQ) | 21.67 |
| Operating Cash Flow (TTM) | -171.51 M |
| Levered Free Cash Flow (TTM) | -101.09 M |
| Return on Assets (TTM) | -16.88% |
| Return on Equity (TTM) | -23.20% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | Celldex Therapeutics, Inc. | Mixed | Bullish |
AIStockmoo Score
-2.5
| Analyst Consensus | NA |
| Insider Activity | NA |
| Price Volatility | -4.5 |
| Technical Moving Averages | -2.5 |
| Technical Oscillators | -0.5 |
| Average | -2.50 |
|
Celldex Therapeutics Inc is a biopharmaceutical firm focused on mast cell biology and the development of therapeutic antibodies. Its pipeline includes monoclonal and bispecific antibodies aimed at treating severe inflammatory, allergic, autoimmune, and other mast cell-mediated diseases. The company operates in a single operating and reportable segment in the business of development, manufacturing and commercialization of novel therapeutics for human health care. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 0.32% |
| % Held by Institutions | 113.13% |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |